银杏达莫注射液治疗早期糖尿病肾病的临床观察

Ginkgo-Dipyridamolum injection for treatment of early diabetic nephropathy

目的观察银杏达莫注射液对早期糖尿病肾病的治疗效果。方法将80例早期糖尿病肾病患者通过随机数字表法分为治疗组和对照组各40例。对照组给予常规治疗，治疗组在常规治疗基础上加用银杏达莫注射液20ml，静脉滴注，1次／d，共3周。治疗前后分别检测尿白蛋白排泄率，血、尿β2-微球蛋白。结果治疗组治疗后尿蛋白排泄率为（45±21）μg／min，对照组为（96±28）μg／min；治疗组血β2-微球蛋白为（2．6±1．3）mg／L，对照组为（3．7±1．2）mg／L；尿β2-微球蛋白治疗组为（40．5±13．2）mg/L，对照组为（40．1±10．8）mg／L，与本组治疗前相比，差异有统计学意义（均P〈0．05）。治疗后2组尿自蛋白排泄率、血β2-微球蛋白均下降，而以治疗组更明显，2组之间差异有统计学意义。对照组治疗前血糖值（12．01±2．14）mmol／L，治疗后（7．91±2．36）mmol／L；治疗组治疗前血糖值（11．91±2．36）mmol／L，治疗后（7．81±2．89）mmol／L。2组与本组治疗前相比，差异有统计学意义（P〈0．05）；2组间治疗后相比，差异无统计学意义。治疗组治疗过程中未见相关药物不良反应。结论银杏达莫注射液对早期糖尿病肾病治疗效果较好，且较安全。

Objective To evaluate the effect of Ginkgo-Dipyridamolum injection on early diabetic nephropathy. Methods Eighty patients with early diabetic nephropathy were divided into two groups： treatment group （n = 40 ）and control group （n = 40 ）. Besides routine therapy, the treatment group was also treated with Ginkgo-Dipyridamolum injection by intravenous infusion（20ml daily）. The course of treatment for both groups was 3 weeks. Urinary albumin excretion rate （UAER） , serum and urinary β2-MG levels were measured before and after the treatment. Results After treatment, UAER and serum β2-MG levels were all decreased with a significant difference between two groups. UAER was （45 ± 21 ） μg/min and （ 96 ± 28 ） μg/min （ P 〈 0.05 ） in treatment group and control group respectively. Serum β2-MG was （ 2.6 ± 1.3 ） mg/L and （ 3.7 ± 1.2 ） mg/L in treatment group and control group respectively. （ P 〈 0.05 ）. Conclusion Ginkgo-Dipyridamolum injection is effective for early diabetic nephropathy.